Back

STELLAR

Official Title

A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy STELLAR Study

Study Details

The purpose of this study is to measure whether eflornithine in combination with lomustine leads to longer survival of patients when compared to lomustine alone, and whether the combination is as safe as lomustine alone.

Principal Investigator

Dr. Milan Chheda

IRB Number

201809080

Eligibility

1. Participants must be at least 18 years of age
2. Participants must have diagnosis of anaplastic astrocytoma that has returned after radiation and chemotherapy

Volunteer Information

For more information about this study, contact Volunteer for Health at:

Back